56.03

1.48% -0.68

Ionis Pharmaceuticals Inc (IONS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$56.71

Offen:

$56.38

24-Stunden-Volumen:

762.58K

Relative Volume:

0.25

Marktkapitalisierung:

$9.31B

Einnahmen:

$1.06B

Nettoeinkommen (Verlust:

$-326.58M

KGV:

-26.65

EPS:

-2.1022

Netto-Cashflow:

$-977.73M

1W Leistung:

-8.90%

1M Leistung:

-1.22%

6M Leistung:

-25.86%

1J Leistung:

-13.25%

1-Tages-Spanne:

$55.76

$56.96

1-Wochen-Bereich:

$52.15

$60.42

52-Wochen-Spanne:

$50.01

$86.74

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Firmenname

Ionis Pharmaceuticals Inc

Sektor

Healthcare (1087)

Branche

Biotechnology (606)

Telefon

(760) 931-9200

Adresse

2855 GAZELLE COURT, CARLSBAD, CA

Mitarbeiter

1,402

Twitter

@ionispharma

Nächster Verdiensttermin

2026-07-29

Neueste SEC-Einreichungen

IONS's Discussions on Twitter

Compare IONS vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IONS Ionis Pharmaceuticals Inc	56.05	9.42B	1.06B	-326.58M	-977.73M	-2.1022
VRTX Vertex Pharmaceuticals Inc	522.51	134.06B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	801.48	83.43B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,002.19	63.00B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.48	56.02B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	209.62	44.44B	742.00K	-1.37B	-1.07B	-7.0731

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-21	Eingeleitet	Canaccord Genuity	Buy
2026-04-10	Fortgesetzt	Raymond James	Outperform
2026-01-28	Fortgesetzt	Barclays	Overweight
2025-10-08	Hochstufung	JP Morgan	Neutral → Overweight
2025-09-26	Hochstufung	Goldman	Sell → Neutral
2025-09-03	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2025-07-31	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2025-07-01	Hochstufung	Barclays	Equal Weight → Overweight
2025-04-07	Eingeleitet	H.C. Wainwright	Buy
2025-03-31	Eingeleitet	Redburn Atlantic	Neutral
2024-08-02	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2024-07-24	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-07-16	Fortgesetzt	Jefferies	Buy
2024-06-14	Hochstufung	Bernstein	Underperform → Mkt Perform
2024-04-10	Hochstufung	Wolfe Research	Peer Perform → Outperform
2024-01-02	Hochstufung	BofA Securities	Neutral → Buy
2023-10-23	Hochstufung	BofA Securities	Underperform → Neutral
2023-09-29	Eingeleitet	Raymond James	Strong Buy
2023-07-31	Hochstufung	Citigroup	Neutral → Buy
2023-06-07	Fortgesetzt	Piper Sandler	Overweight
2023-05-04	Hochstufung	Citigroup	Sell → Neutral
2023-03-21	Eingeleitet	Bernstein	Underperform
2022-12-21	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-09-09	Fortgesetzt	Morgan Stanley	Overweight
2022-07-18	Fortgesetzt	Oppenheimer	Outperform
2022-03-31	Fortgesetzt	Piper Sandler	Overweight
2022-03-01	Eingeleitet	Citigroup	Sell
2022-03-01	Eingeleitet	Guggenheim	Buy
2022-02-01	Herabstufung	BofA Securities	Buy → Underperform
2021-12-14	Hochstufung	William Blair	Mkt Perform → Outperform
2021-05-07	Hochstufung	UBS	Sell → Neutral
2021-03-01	Hochstufung	Barclays	Underweight → Equal Weight
2020-12-16	Eingeleitet	UBS	Sell
2020-12-15	Hochstufung	Cowen	Market Perform → Outperform
2020-09-14	Fortgesetzt	JP Morgan	Neutral
2020-09-02	Eingeleitet	The Benchmark Company	Hold
2020-06-01	Fortgesetzt	Oppenheimer	Outperform
2020-05-13	Eingeleitet	RBC Capital Mkts	Outperform
2020-03-05	Eingeleitet	Citigroup	Buy
2019-12-13	Eingeleitet	Oppenheimer	Outperform
2019-11-13	Eingeleitet	BofA/Merrill	Buy
2019-11-07	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2019-09-10	Hochstufung	Bernstein	Mkt Perform → Outperform
2018-08-08	Bestätigt	Stifel	Hold
2018-08-07	Bestätigt	Stifel	Hold
2018-05-08	Herabstufung	Evercore ISI	Outperform → In-line
2017-10-06	Fortgesetzt	Goldman	Sell
2017-08-17	Eingeleitet	Evercore ISI	Outperform
2017-08-09	Bestätigt	Stifel	Hold
2017-03-10	Herabstufung	Goldman	Neutral → Sell
2016-12-28	Bestätigt	BMO Capital Markets	Outperform
2016-12-27	Bestätigt	Leerink Partners	Mkt Perform

Alle ansehen

Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten

Sep 08, 2026

Raymond James cuts Ionis Pharmaceuticals price target on trial miss By Investing.com - Investing.com Canada

Sep 08, 2026

Retatrutide clears BLA bar while Wainua stumbles in busy July for trials - BioWorld News

Sep 08, 2026

IONS Maintained by Goldman Sachs -- Price Target Lowered to $56 - GuruFocus

Sep 08, 2026

BMO cuts Ionis Pharmaceuticals stock price target on drug failure By Investing.com - Investing.com Canada

Sep 08, 2026

Amgen drops on Novartis trial setback for heart therapy; BMO downgrades - Seeking Alpha

Sep 08, 2026

Ionis Pharmaceuticals gets $85 price target des... - Pluang

Sep 08, 2026

H.C. Wainwright cuts Ionis stock price target to $100 on pelacarsen removal - Investing.com

Sep 08, 2026

Canaccord cuts Ionis stock price target to $85 on pelacarsen trial miss - Investing.com

Sep 08, 2026

Needham reiterates Ionis stock rating after trial failure By Investing.com - Investing.com India

Sep 08, 2026

Ionis Stock Sinks 10% as Analysts Cut Targets After Pelacarsen Trial Miss - TipRanks

Sep 08, 2026

IONS Maintained by HC Wainwright & Co. -- Price Target Lowered to $100 - GuruFocus

Sep 08, 2026

Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga

Sep 08, 2026

Why Is Novartis Stock Falling Today?Novartis (NYSE:NVS), Ionis Pharmaceuticals (NASDAQ:IONS), Royalty - Benzinga

Sep 08, 2026

Ionis Pharmaceuticals Shares Fall After Pelacarsen Phase 3 Trial Misses Primary Endpoint - Yahoo Finance

Sep 08, 2026

Why is Ionis Pharmaceuticals stock tumbling today? By Investing.com - Investing.com India

Sep 08, 2026

Sep 07, 2026